AC
ATNM icon

Armistice Capital’s Actinium Pharmaceuticals ATNM Stock Holding History

Armistice Capital’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-203,333
Closed -$2.23M – 75
2018
Q1 		$2.23M Buy
203,333
+54,533
+37% +$927K 0.17% 56
2017
Q4 		$2.96M Buy
148,800
+2,733
+2% +$55K 0.3% 55
2017
Q3 		$2.52M Buy
+146,067
New +$3.21M 0.3% 55

Other funds holding ATNM

DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
CAN
Cetera Advisor Networks El Segundo, California $20.2B AUM 22.31% 1-Year Est. Return

Armistice Capital's ATNM Position: Q2 2018 in Review

Armistice Capital sold out of Actinium Pharmaceuticals (ATNM) in Q2 2018, closing a stake of 203,333 shares — an estimated $2.23M sold.

Armistice Capital first reported a position in ATNM in Q3 2017 and held it in 3 quarters. The position peaked at $2.96M in Q4 2017. 42 funds tracked by Wall St. Rank hold ATNM as of Q2 2018.

  • Armistice Capital reported no remaining Actinium Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Armistice Capital sold 203,333 Actinium Pharmaceuticals shares in Q2 2018, an estimated $2.23M.
  • Armistice Capital first reported a position in Actinium Pharmaceuticals in Q3 2017 and held it in 3 quarters.
  • Armistice Capital's Actinium Pharmaceuticals position peaked at $2.96M in Q4 2017.
  • 42 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q2 2018.

Based on Armistice Capital's 13F filing for Q2 2018, filed 14 Aug 2018.